Moderna Diversifies Pipeline With New Vaccines and Cancer Therapy
Moderna is expanding its product portfolio into oncology and respiratory vaccines to reduce reliance on coronavirus vaccine revenue and drive growth through 2030.
Moderna is executing a strategic turnaround to diversify its revenue streams following the decline in pandemic-era vaccine demand. The biotechnology company has expanded its commercial portfolio to include a respiratory syncytial virus vaccine and a recently approved mRNA flu vaccine. In Europe, the company has already secured approval for a combined coronavirus and flu vaccine.
Financial forecasts for 2026 project revenue growth of up to 10%, with potential earnings reaching $2 billion. This shift is supported by a 500% increase in stock value this year, though analysts indicate further growth depends on the commercialization of pipeline candidates for rare diseases and oncology by 2030.
A central component of this strategy is the personalized cancer vaccine mRNA-4157, developed in collaboration with Merck. Recent phase 3 trial data demonstrated that the vaccine, when used alongside Merck's Keytruda, met goals for recurrence-free survival in patients with melanoma.
